Joaquin Arribas

Joaquin Arribas

UNVERIFIED PROFILE

Are you Joaquin Arribas?   Register this Author

Register author
Joaquin Arribas

Joaquin Arribas

Publications by authors named "Joaquin Arribas"

Are you Joaquin Arribas?   Register this Author

74Publications

2015Reads

20Profile Views

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1.

Cancers (Basel) 2020 Mar 13;12(3). Epub 2020 Mar 13.

Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12030670DOI Listing
March 2020

TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells.

Cancer Lett 2019 07 27;453:34-44. Epub 2019 Mar 27.

Instituto de Biología Molecular y Celular del Cáncer. CSIC-IBSAL, Salamanca, Spain; CIBERONC, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.03.042DOI Listing
July 2019

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503.

Sci Rep 2019 03 4;9(1):3352. Epub 2019 Mar 4.

Section for Cell Biology and Physiology, Department of Biology, Faculty of Science, University of Copenhagen, Universitetsparken 13, DK-2100, Copenhagen, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-39733-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399295PMC
March 2019

TGFβ-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1.

Cancer Res 2019 01 19;79(1):33-46. Epub 2018 Oct 19.

Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Unidad Asociada CSIC, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-0753DOI Listing
January 2019

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

J Clin Oncol 2018 11 21;36(31):3134-3143. Epub 2018 Sep 21.

Cristina Cruz and Judith Balmaña, Vall d'Hebron Hospital; Cristina Cruz, Alba Llop-Guevara, Joaquín Arribas, Ana Vivancos, Violeta Serra, and Judith Balmaña, Vall d'Hebron Institute of Oncology; José A. Pérez Fidalgo, Ana Lluch, Joaquín Arribas, and Violeta Serra, Centro de Investigación Biomédica en Red; Joaquín Arribas, Institució Catalana de Recerca i Estudis Avançats, Barcelona; José A. Pérez Fidalgo and Ana Lluch, Hospital Clínico de Valencia, Valencia; Cristian Fernández, Carmen Kahatt, Carlos M. Galmarini, Arturo Soto-Matos, Vicente Alfaro, and Aitor Pérez de la Haza, PharmaMar, Madrid; Silvia Antolin, Complejo Universitario Hospitalario La Coruña, La Coruña; Rafael Lopez, Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Judy E. Garber, Dana Farber Cancer Institute; Nadine M. Tung, Beth Israel Deaconess Medical Center; José Baselga and Steven J. Isakoff, Massachusetts General Hospital Cancer Center, Boston, MA; Banu K. Arun, MD Anderson Cancer Center, Houston, TX; Melinda L. Telli, Stanford University School of Medicine, Stanford, CA; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; and Linda Vahdat, Weill Cornell Medicine, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.6558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209089PMC
November 2018

Coamplification of protects -amplified breast cancers from targeted therapy.

Proc Natl Acad Sci U S A 2018 03 23;115(11):E2594-E2603. Epub 2018 Feb 23.

Department of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1717820115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856537PMC
March 2018

Targeting the EGF/HER Ligand-Receptor System in Cancer.

Curr Pharm Des 2016 ;22(39):5887-5898

Instituto de Biología Molecular y Celular del Cáncer-CIC, Campus Miguel de Unamuno, s/n, 37007- Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1381612822666160715132233DOI Listing
December 2017

Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis.

Oncotarget 2017 Nov 3;8(55):93688-93703. Epub 2017 Oct 3.

Centro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, CSIC-Universidad de Sevilla-Universidad Pablo de Olavide, Sevilla, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21458DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706828PMC
November 2017

Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts.

Oncotarget 2016 10;7(42):67956-67965

Breast Surgical Unit, Breast Cancer Center, Hospital Universitario Vall d´Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.11815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356531PMC
October 2016

Cancer network activity associated with therapeutic response and synergism.

Genome Med 2016 08 24;8(1):88. Epub 2016 Aug 24.

Breast Cancer and Systems Biology Lab, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Gran via 199, L'Hospitalet del Llobregat, Barcelona, 08908, Catalonia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-016-0340-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995628PMC
August 2016

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.

PLoS One 2015 15;10(6):e0129876. Epub 2015 Jun 15.

Preclinical Oncology Program, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Campus de la UAB, 08193, Bellaterra, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0129876PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467984PMC
March 2016

Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence.

Breast Cancer Res 2015 Aug 12;17:106. Epub 2015 Aug 12.

Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Psg. Vall d'Hebron 119-129, Barcelona, 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-015-0619-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532141PMC
August 2015

Effect of cellular senescence on the growth of HER2-positive breast cancers.

J Natl Cancer Inst 2015 May 13;107(5). Epub 2015 May 13.

Preclinical Research (MZF, BM, RV, ALG, ME, JV, JA) and Clinical Research Programs (ITR), Vall d'Hebron Institute of Oncology, Barcelona, Spain; Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Campus de la UAB, Bellaterra, Spain (JA); Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain (JA).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv020DOI Listing
May 2015

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

J Natl Cancer Inst 2014 Nov 24;106(11). Epub 2014 Sep 24.

*Authors contributed equally to this work.Affiliations of authors: Preclinical Research (JLPP, BM, ME, RV, MZF, KP, VS, AP, JA) and Clinical Research Programs (PN, JC, ITR), Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain (VP); Human Oncology and Pathogenesis Program (HOPP) and Memorial Sloan Kettering Cancer Center, New York, NY (MS, JB); Instituto de Biología Molecular y Celular del Cáncer, Campus Miguel de Unamuno, Salamanca, Spain (AP); Lineberger Comprehensive Cancer Center, Chapel Hill, NC (CMP); Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Campus de la UAB, Bellaterra, Spain (JA); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain (JA).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju291DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271027PMC
November 2014

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

Eur J Cancer 2014 Oct 12;50(15):2725-34. Epub 2014 Aug 12.

Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.07.004DOI Listing
October 2014

Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion.

J Proteome Res 2014 Aug 15;13(8):3706-3721. Epub 2014 Jul 15.

Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB) , Psg. Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/pr500304g
Publisher Site
http://dx.doi.org/10.1021/pr500304gDOI Listing
August 2014

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

Cancer Discov 2013 Nov 15;3(11):1238-44. Epub 2013 Aug 15.

1Vall d'Hebron Institut d'Oncologia; 2Vall d'Hebron Institut de Recerca; 3Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona; 4Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain; and 5Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0132DOI Listing
November 2013

The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells.

FASEB J 2012 Nov 2;26(11):4481-94. Epub 2012 Aug 2.

Vascular Biology Department, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.

View Article

Download full-text PDF

Source
http://www.fasebj.org/doi/10.1096/fj.12-205906
Publisher Site
http://dx.doi.org/10.1096/fj.12-205906DOI Listing
November 2012

SFRPs act as negative modulators of ADAM10 to regulate retinal neurogenesis.

Nat Neurosci 2011 May 10;14(5):562-9. Epub 2011 Apr 10.

Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nn.2794DOI Listing
May 2011

p95HER2 and breast cancer.

Cancer Res 2011 Mar 22;71(5):1515-9. Epub 2011 Feb 22.

Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-3795DOI Listing
March 2011

HER2 fragmentation and breast cancer stratification.

Clin Cancer Res 2010 Aug 3;16(16):4071-3. Epub 2010 Aug 3.

Vall d'Hebron Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-1501DOI Listing
August 2010

The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration.

J Biol Chem 2010 Jan 13;285(4):2463-73. Epub 2009 Nov 13.

Medical Oncology Research Program, Research Institute Foundation and Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Psg. Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M109.055129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807303PMC
January 2010

ADAM17 as a therapeutic target in multiple diseases.

Curr Pharm Des 2009 ;15(20):2319-35

Institució Catalana de Recerca i Estudis Avançats (ICREA), Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138161209788682398DOI Listing
October 2009

HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation.

J Biol Chem 2009 Sep 8;284(37):25302-13. Epub 2009 Jul 8.

Medical Oncology Research Program, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M109.001982DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757232PMC
September 2009

Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17.

Biol Chem 2008 Aug;389(8):1075-84

Medical Oncology Research Program, Vail d'Hebron University Hospital Research Institute, Psg. Vail d'Hebron 119-129, Universitat Autonoma de Barcelona, E-08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/bc.2008.121DOI Listing
August 2008

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

J Natl Cancer Inst 2007 Apr;99(8):628-38

Medical Oncology Program, Medical Oncology Department, Vall d'Hebron University Hospital and Research Institute, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djk134DOI Listing
April 2007

Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors.

J Biol Chem 2007 Mar 16;282(11):8325-31. Epub 2007 Jan 16.

Medical Oncology Research Program, Vall d'Hebron University Hospital Research Institute, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M608826200DOI Listing
March 2007

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

EMBO J 2006 Jul 22;25(13):3234-44. Epub 2006 Jun 22.

Medical Oncology Research Program, Vall d'Hebron University Hospital Research Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.emboj.7601191DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1500971PMC
July 2006

ADAMs, cell migration and cancer.

Cancer Metastasis Rev 2006 Mar;25(1):57-68

Medical Oncology Research Program, Vall d'Hebron University Hospital Research Institute, 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-006-7889-6DOI Listing
March 2006

Recycling of cell surface pro-transforming growth factor-{alpha} regulates epidermal growth factor receptor activation.

J Biol Chem 2005 Nov 29;280(44):36970-7. Epub 2005 Aug 29.

Medical Oncology Research Program, Vall d'Hebron Research Institute University Hospital, 119-129 Psg. Vall d'Hebron, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M504425200DOI Listing
November 2005

N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity.

Biochem J 2005 Jul;389(Pt 1):161-72

Instituto de Microbiología Bioquímica and Centro de Investigación del Cáncer, CSIC-Universidad de Salamanca, Campus Miguel de Unamuno, 37007-Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BJ20041128DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1184548PMC
July 2005

Who will benefit from treatment against EGFR?

Lancet Oncol 2005 May;6(5):257-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(05)70142-XDOI Listing
May 2005

Matrix metalloproteases and tumor invasion.

Authors:
Joaquín Arribas

N Engl J Med 2005 May;352(19):2020-1

Medical Oncology Research Program, Vall d'Hebron University Hospital Research Institute, Barcelona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcibr055002DOI Listing
May 2005

Melanoma metastasis is associated with enhanced expression of the syntenin gene.

Oncol Rep 2004 Aug;12(2):221-8

Department of Pathology, Heidelberg University Clinics, D-69120 Heidelberg, Germany.

View Article

Download full-text PDF

Source
August 2004

Treating cancer's kinase 'addiction'.

Nat Med 2004 Aug;10(8):786-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm0804-786DOI Listing
August 2004

The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1.

J Biol Chem 2004 Feb 12;279(9):7721-33. Epub 2003 Dec 12.

Departamento de Biología Celular, Instituto de Fisiología Celular, Universidad Autónoma de México, Apartado Postal 70-246, Mexico City, Distrito Federal 04510, México.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M306499200DOI Listing
February 2004

Inactivating mutations block the tumor necrosis factor-alpha-converting enzyme in the early secretory pathway.

Biochem Biophys Res Commun 2004 Feb;314(4):1028-35

Laboratori de Recerca Oncològica, Servei d'Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Psg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2003.12.186DOI Listing
February 2004

Shedding of plasma membrane proteins.

Curr Top Dev Biol 2003 ;54:125-44

Laboratori de Recerca Oncològica, Servei d'Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0070-2153(03)54007-8DOI Listing
December 2003

Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding.

J Biol Chem 2003 Jul 24;278(28):25933-9. Epub 2003 Apr 24.

Laboratori de Recerca Oncològica, Servei d'Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Psg. Vall d'Hebron 119-129, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M301673200DOI Listing
July 2003

TACE is required for the activation of the EGFR by TGF-alpha in tumors.

EMBO J 2003 Mar;22(5):1114-24

Laboratori de Recerca Oncològica, Servei d'Oncologia Medica, Hospital Universitari Vall d'Hebron, Psg Vall d'Hebron 119-129, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/emboj/cdg111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC150344PMC
March 2003

The proteasome is a major autoantigen in multiple sclerosis.

Brain 2002 Dec;125(Pt 12):2658-67

Instituto de Investigaciones Biomédicas Alberto Sols, UAM-CSIC, Facultad de Medicina, UAM, Servicio de Inmunología, Hospital Universitario La Paz, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/awf274DOI Listing
December 2002

Protein ectodomain shedding.

Chem Rev 2002 Dec;102(12):4627-38

Laboratori de Recerca Oncològica, Servei d'Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Psg. Vall d'Hebron 119-129, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/cr010202tDOI Listing
December 2002